Best deals to access real time data!
SMALL CAP PRO
DDE w/Realtime (Monthly)
VAT not included
|Company Name||Stock Ticker Symbol||Market||Type||ISIN|
|Accentia Biopharmaceuticals, Inc.||ABPI||Other OTC||Common Stock|
|Price Change||Change Percent||Stock Price||High Price||Low Price||Open Price||Close Price||Last Traded|
|Last Trade Time||Type||Quantity||Stock Price||Currency|
Accentia Biopharmaceuticals, Inc. Financials
|Market Cap||Shares in Issue||Profit/Loss||Earnings Per Share (EPS)||PE Ratio||Float|
|$ 8.98k||89.76M||$ -4.32M||-||-||-|
|Short Interest||Dividends Per Share||Dividend Yield||Ex-Div Date||Insider B/S||Insider % Owned|
Accentia Biopharmaceuticals, Inc. News
|1/15/2016||12:58||Edgar (US Regulatory)||Revocation of Exchange Act Registration Pursuant to Section..|
Historical ABPI Price Data
|Period †||Open||High||Low||VWAP||Min Vol||Max Vol||Avg. Daily Vol [m]||Change||%|
Accentia Biopharmaceuticals, Inc. Description
|Accentia Biopharmaceuticals, Inc. is engaged in the business of commercializing patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications.
Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID., a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin's lymphoma; Revimmune(c), a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase(c), a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.
Additionally, Accentia's wholly-owned subsidiary, Analytica International, markets pharmaceutical consulting services.
Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc. and Accentia also maintains a royalty interest in Biovest's biologic products. Accentia is a portfolio company of the Hopkins Capital Group.